The Company has several warrant programs linked to the development of PXL01. Holders of these warrants are Technomark Group USA LLC, Kentron Biotechnology Pvt Ltd and PharmaResearch Co. Ltd.
The exercise price for the warrants are SEK 13.30 per share, but will be adjusted to the quota value (SEK 0.04) if certain milestones are met in the development program. The warrants’ maturity is 31 December 2022.
|No of warrants||Holder||No of shares fully exercised|
|45 455||PharmaResearch Co. Ltd||681,825|